Focus: Pliant Therapeutics is a clinical-stage biotech focused on treatments for fibrotic diseases, with active programs in respiratory and oncology indications. The company is headquartered in South San Francisco and operates as a publicly traded mid-cap biotech.
Profile data last refreshed 6h ago · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
2 added, 1 removed. Backfill posture.
Career fit for scientists/clinicians seeking deep technical work on fibrosis biology in a focused biotech, but timing and stability risks warrant scrutiny of recent headcount reduction.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Pliant Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Pliant Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Pliant Therapeutics, Inc. expected to post a loss of 34 cents a share - Earnings Preview - TradingView
Pliant Therapeutics, Inc. expected to post a loss of 34 cents a share - Earnings Preview TradingView
PLRX|Pliant Therapeutics Inc|Price:1.050|Chg%:+0.010 - TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.050|Chg%:+0.010 TradingKey
Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Pliant Therapeutics Inc (PLRX) Financial Health: Profitability & Balance Sheet Analysis TradingKey
Pliant Therapeutics Inc (PLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pliant Therapeutics Inc (PLRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages TradingKey
Pliant Therapeutics Inc (PLRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Pliant Therapeutics Inc (PLRX) Risk Assessment: Volatility, Financial Risk & Investment Risk TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.075|Chg%:-0.005 - TradingKey
PLRX|Pliant Therapeutics Inc|Price:1.075|Chg%:-0.005 TradingKey
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: state DOL filings, aggregated via Big Local News
Recent layoff is a red flag for cash constraints; confirm company runway, Phase 2 cash-out timeline, and post-trial financing plans before accepting offer.
Recent peer-reviewed publications with author affiliations at this company
Bexotegrast for treatment of idiopathic pulmonary fibrosis (BEACON-IPF): study protocol for a multinational, phase 2b/3, double-blind, randomised, multicentre, controlled trial.
Artificial intelligence, machine learning-based automated fibrosis quantification in preclinical models of pulmonary fibrosis.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo